News

HPV testing best predicts cervical neoplasia risk

Publish date: April 2, 2013

 

AT THE ANNUAL MEETING ON WOMEN'S CANCER

Dr. Wright disclosed that he is a consultant for Roche Molecular Systems, BD Diagnostics, Cepheid, and Hologic. The trial was sponsored by Roche Molecular Systems.

Pages

Recommended Reading

Previous abortion no longer a risk factor for preterm birth
MDedge ObGyn
Trial of labor after C-section uncommon, but often successful
MDedge ObGyn
Breast cancer: Cardiac risk increases with radiation dose to heart
MDedge ObGyn
Cervical pessaries improve outcomes in some multiple pregnancies
MDedge ObGyn
Being postmenopausal doubles hepatic steatosis risk
MDedge ObGyn
Shorter time to delivery seen with misoprostol vs. dinoprostone vaginal insert
MDedge ObGyn
High-risk HPV infection more than doubles odds of preeclampsia
MDedge ObGyn
Placental abruption a strong risk factor for long-term CVD death
MDedge ObGyn
ACOG: Balance risks when considering early deliveries
MDedge ObGyn
Skin capillary density drop reliably predicts preeclampsia
MDedge ObGyn